Eagles trade for Jets CB Michael Carter II to bolster their secondary for a title defense.
Novo Nordisk makes a bold $9B bid to acquire Metsera, a U.S. biotech firm, in a bid to outpace Pfizer's existing $4.9B deal and regain leadership in the competitive obesity drug market.
Altria's Q3 earnings beat estimates, but shares fell on a weak outlook and persistent category challenges.
Eagles trade for Jets CB Michael Carter II to bolster their secondary for a title defense.
Novo Nordisk makes a bold $9B bid to acquire Metsera, a U.S. biotech firm, in a bid to outpace Pfizer's existing $4.9B deal and regain leadership in the competitive obesity drug market.
Altria's Q3 earnings beat estimates, but shares fell on a weak outlook and persistent category challenges.
